Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Authors
Keywords
-
Journal
BLOOD
Volume 117, Issue 23, Pages 6287-6296
Publisher
American Society of Hematology
Online
2011-03-22
DOI
10.1182/blood-2011-01-328484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 17-DMAG targets the nuclear factor- B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
- (2010) E. Hertlein et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro
- (2010) Panayiotis Panayiotidis et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
- (2010) Thomas S. Lin et al. LEUKEMIA & LYMPHOMA
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rituximab in Chronic Lymphocytic Leukemia
- (2010) Samantha M. Jaglowski et al. SEMINARS IN HEMATOLOGY
- Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
- (2009) M. Niedermeier et al. BLOOD
- In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia
- (2009) C. Calissano et al. BLOOD
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
- (2009) M. P. Quiroga et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
- (2009) Maike Buchner et al. CANCER RESEARCH
- The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression
- (2009) A D Baudot et al. ONCOGENE
- Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia
- (2008) L. Trentin et al. BLOOD
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
- (2008) Leslie A. Andritsos et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More